High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma
Related Experiment Video
Updated: Aug 2, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Niklas Klümper1, Alexander Cox2, Markus Eckstein3
1Department of Urology, University Hospital Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany; Institute of Experimental Oncology, University Hospital Bonn (UKB), Bonn, Germany.
Objectives:
The development of reliable biomarkers for the prediction of immune checkpoint inhibition (ICI) response in patients with metastatic renal cell carcinoma (mRCC) and urothelial carcinoma (mUC) remains an unresolved challenge. Conventional ICI biomarkers typically focus on tumor-related factors such as PD-L1 expression. However, a comprehensive evaluation of the predictive value of serum electrolyte levels, a so far widely unexplored area, is still pending.
Methods:
We conducted a post-hoc analysis of baseline sodium, potassium, chloride, magnesium and calcium levels in two independent phase 3 clinical trials: IMvigor211 for mUC comparing atezolizumab to chemotherapy, and IMmotion151 for mRCC comparing atezolizumab+bevacizumab to sunitinib. This analysis aimed to evaluate the prognostic and predictive value of these electrolyte levels in these clinical settings. A total of 1787 patients (IMvigor211 n = 901; IMmotion151 n = 886) were analyzed.
Results:
We found a linear correlation of baseline serum sodium and chloride with prognosis across both trials, which was not found for potassium, magnesium and calcium. In multivariate analysis, the prognostic capacity of sodium was limited to patients receiving ICI as compared to the control group. Interestingly, in both studies, the chance of achieving an objective response was highest in the patient subgroup with high baseline serum sodium levels of > 140 mmol/L (IMmotion151: Complete response in 17.9% versus 2.0% in patients with mRCC with baseline sodium < 135 mmol/L). Serum sodium outperformed tumor PD-L1 expression as a predictor for immunotherapy efficacy.
Conclusions:
Patients exhibiting elevated serum sodium levels derive the greatest benefit from immunotherapy, suggesting that baseline serum concentration could serve as a valuable and cost-effective predictive biomarker for immunotherapy across entities.
Insights
Elevated serum sodium levels predict a better response to immune checkpoint inhibition (ICI) in metastatic renal cell carcinoma and urothelial carcinoma. This simple blood test may serve as a cost-effective biomarker for immunotherapy efficacy.
Area of Science:
- Oncology
- Immunotherapy
- Biomarker Discovery
Background:
- Predicting response to immune checkpoint inhibition (ICI) in metastatic renal cell carcinoma (mRCC) and urothelial carcinoma (mUC) is challenging.
- Current biomarkers like PD-L1 focus on tumor factors, neglecting other potential predictors.
- Serum electrolyte levels have been largely unexplored as predictive biomarkers for ICI response.
Purpose of the Study:
- To evaluate the prognostic and predictive value of baseline serum electrolyte levels (sodium, potassium, chloride, magnesium, calcium) in patients with mRCC and mUC treated with ICI.
- To compare the efficacy of serum electrolytes as biomarkers against conventional markers like PD-L1 expression.
Main Methods:
- Post-hoc analysis of serum electrolyte levels from two independent phase 3 clinical trials (IMvigor211 and IMmotion151).
- Analysis included 1787 patients with mRCC and mUC.
- Prognostic and predictive values were assessed using multivariate analysis.
Main Results:
- Baseline serum sodium and chloride levels showed a linear correlation with prognosis in both trials.
- Elevated serum sodium (>140 mmol/L) was associated with a significantly higher objective response rate to ICI.
- Serum sodium outperformed PD-L1 expression in predicting immunotherapy efficacy.
Conclusions:
- Elevated baseline serum sodium levels are associated with superior outcomes in patients receiving immunotherapy.
- Serum sodium concentration represents a promising, cost-effective predictive biomarker for immunotherapy response across different cancer types.
More Related Videos
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Kidney Transplant III: Nursing Management
Serum Studies: Renal Function Tests

